AbbVie’s Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
- Friday, October 29, 2021, 7:14
- PR Newswire
- Add a comment
NORTH CHICAGO, Ill., Oct. 29, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR®) as an adjunctive treatment for patients with…
About the Author
admin has written 20652 stories on this site.